Yan Qing
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: April 22, 2026
Baseline Nutritional Indices as Prognostic Indicators in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Treated with the PD-L1 Inhibitor KL-A167: A Secondary Analysis of the KL-A167 Trial.
Journal: Cancer management and research
Published: March 30, 2026
Association of basal thyroid function with clinical outcomes in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-L1 inhibitor KL-A167: a multicenter post hoc analysis.
Journal: Endocrine connections
Published: January 29, 2026
Correction: Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors.
Journal: Cancer immunology, immunotherapy : CII
Published: September 29, 2025
Correction: Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167).
Journal: Cancer immunology, immunotherapy : CII
Published: September 29, 2025
Prognostic Impact of Advanced Lung Cancer Inflammation Index (ALI) on Immunotherapy Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter Post Hoc Analysis.
Journal: Journal of inflammation research
Published: June 15, 2025
Corrigendum: Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors.
Journal: Frontiers in oncology
Published: April 11, 2025
Uniconazole-mediated growth regulation in Ophiopogon japonicus: yield maximization vs. medicinal quality trade-offs.
Journal: Frontiers in plant science
Published: December 10, 2024
Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors.
Journal: Frontiers in oncology
Published: December 04, 2024
Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study.
Journal: Oral oncology
Published: September 09, 2024
Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors.
Journal: Cancer immunology, immunotherapy : CII
Published: August 22, 2024
Last Updated: 09/26/2026